Satralizumab represents a potential new approach to treating neuromyelitis optica spectrum disorder (NMOSD), a rare, debilitating disease often misdiagnosed as multiple sclerosis (MS)… Click here…
Press
September 12, 2019 | Beverly Hills, CA — Genentech, a member of the Roche Group, announced positive results from one of its phase III clinical…
The 46-year-old woman suddenly felt too weak to stand. She slowly lowered herself to her kitchen floor. She’d been vomiting for the past five weeks,…
Featured Videos
